Intec Pharma Ltd. (NTEC): Why Is It Down -4.13 Percent Today

The biggest losers of the session on the Wall Street include Intec Pharma Ltd. (NASDAQ:NTEC), which fell -0.04 points or -4.13% to trade at $0.8 as last check. The stock closed last session at $0.84 and sets an active trading volume day with a reported 443449 contracts so far this session. NTEC shares had a relatively better volume day versus average trading capacity of 1.86 million shares, but with a 26.02 million float and a 19.31% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for NTEC stock indicates that the average analyst price target is $8.83 per share. This means the stock has a potential increase of 1003.75% from where the NTEC share price has been trading recently which is between $0.76 and $0.9. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $0.5.

The shorts are climbing into Intec Pharma Ltd. (NTEC) stock. The latest set of short interest data was released on 15 August 2019, and the numbers show a rise in short interest in NTEC shares. While short interest still represents only 7.85% of NTEC’s float, the number of shares shorted have risen by 941316. The number of shares shorted advanced to 2042558 shares, up from 1101242 shares during the preceding fortnight. With average daily trading volumes at 2361662 shares, days to cover decreased to about 1 days. The most recent news story about the stock that appeared in Yahoo Finance‘s news section was titled “Intec Pharma to Participate in September Investment Conferences” and dated September 03, 2019.

During the recent trading session for Intec Pharma Ltd. (NASDAQ:NTEC), the company witnessed their stock rise $0.14 over a week and surge $0.24 from the price 20 days ago. When compared to their established 52-week high of $9.25, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 02/22/19. The recent low of $0.41 stood for a -91.34% since 08/13/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 0 is also allocated to the stock. Since the beta is less than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.

Looking at the current readings for Intec Pharma Ltd., the two-week RSI stands at 39.3. This figure suggests that NTEC stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current NTEC readings is similarly very revealing as it has a stochastic reading of 75.18% at this stage. This figure means that NTEC share price today is being oversold.

Technical chart claims that Intec Pharma Ltd. (NTEC) would settle between $0.9/share to $0.97/share level. However, if the stock price goes below the $0.76 mark, then the market for Intec Pharma Ltd. becomes much weaker. If that happens, the stock price might even plunge as low as $0.69 for its downside target. The stock is currently in the green zone of MACD, with the indicator reading 0.1. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.

Analysts at Maxim Group lifted target price for shares of NTEC but were stick to Buy recommendation for the stock in their opinion released on March 26. The price target has been raised from $8 to $12. Ladenburg Thalmann, analysts launched coverage of Intec Pharma Ltd. (NASDAQ:NTEC) stock with a Buy recommendation, according to their flash note issued to investors on February 28. Analysts at H.C. Wainwright, made their first call for the equity with a Buy recommendation, according to a research note that dated back to February 26.

NTEC equity has an average rating of 2.6, with the figure leaning towards a bullish end. 5 analysts who tracked the company were contacted by Reuters. Amongst them, 4 rated the stock as a hold while the remaining 1 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 1 analysts rated Intec Pharma Ltd. (NASDAQ:NTEC) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.

Moving on, NTEC stock price is currently trading at 0X forward 12-month Consensus EPS estimates, and its P/E ratio is NA while for the average stock in the same group, the multiple is -6.49. Intec Pharma Ltd. current P/B ratio of 0.78 means it is trading at a discount against its industry’s 3.44.